Tokiwa Phytochemical Co., Ltd. Announces New Cutting-Edge Study Supporting Benefits of SIRTMAX (R) on Healthier Life Expectancy
The study led by Tokiwa and Professor Koji Nagata reveals that quercetin 3,5,7,3,4-pentamethyl ether (KPMF-8), an active compound of SIRTMAX (R), directly binds with SIRT1 protein and activates SIRT1 far effectively than resveratrol (well-known SIRT activator).
- The study led by Tokiwa and Professor Koji Nagata reveals that quercetin 3,5,7,3,4-pentamethyl ether (KPMF-8), an active compound of SIRTMAX (R), directly binds with SIRT1 protein and activates SIRT1 far effectively than resveratrol (well-known SIRT activator).
- KPMF-8 interacts with SIRT1 directly and stimulates SIRT1 activity by enhancing the binding affinity of SIRT1 with its substrate, Ac-p53 peptide.
- The binding affinity between SIRT1 and Ac-p53 peptide was enhanced 8.2-fold by KPMF-8, but only 1.4-fold by resveratrol.
- What\'s more, SIRTMAX (R) is 5 times more potent than resveratrol in activating SIRT1.